How much do GLP-1 medications cost?

Mostly people whose insurance covers the drug but whose cost-sharing is tied to list price: those on a high-deductible plan who have not met the deductible yet, or those with coinsurance (a percentage of the price rather than a flat copay). Novo Nordisk named exactly these groups as the ones its 2027 list-price cut is meant to help. If you are in one of them, ask your plan what your cost-sharing is calculated from before assuming the self-pay route is more expensive.

Because several forces landed at once: competition between the two manufacturers, the end of the drug shortages, direct-to-patient sales, and federal pricing agreements. Treat any price you read, including the ones on this page, as a snapshot with a date on it.

Because your plan covers diabetes treatment and excludes weight-loss treatment, and the two brands carry different approved uses even though the active ingredient is the same. A prescription for a diabetes brand written for weight loss alone is typically not what the plan agreed to pay for, and it may also fall outside the manufacturer's savings card terms.

Prior authorization means your prescriber has to send the plan information showing you meet its criteria before the plan will pay. For weight-management brands, plans often ask for documented BMI, weight-related conditions, and sometimes a record of prior weight-loss efforts or participation in a lifestyle program. Approvals are commonly time-limited, so a renewal may come up even when nothing about your treatment has changed.

If a claim is denied, the denial letter should say why and how to appeal. A denial for missing paperwork is a different problem from a plan that excludes the drug class altogether.

No. The manufacturer cards exclude government beneficiaries, and that includes Medicare Advantage and Part D plans even when you also have other coverage. Medicare has its own separate route, described below.

Then the covered-plan card price does not apply. Both manufacturers point people in this situation to their self-pay programs instead, which are priced independently of your insurance.

Generally no. Self-pay prescriptions are processed outside your insurance, and TrumpRx.gov's terms say people using the self-pay offer cannot seek reimbursement or apply it toward deductibles. That matters if you expect to meet your deductible anyway this year.

TrumpRx.gov is a federal website that lists manufacturers' self-pay offers. For these two drugs it points to the same programs described above: a pharmacy coupon for the Wegovy pen, and LillyDirect for Zepbound vials. It is for self-pay purchases only, made outside any insurance or government coverage.

Often, yes, but confirm with your plan administrator. IRS Publication 502 counts prescribed drugs as medical expenses, and counts weight-loss treatment when it treats a disease diagnosed by a physician, such as obesity, but not weight loss for appearance or general health. HSA rules use the same definition of medical care. Lilly labels its self-pay Zepbound as HSA/FSA eligible with the caveat that eligibility may vary by plan. This is general information, not tax advice.

Per Medicare.gov, you must be 18 or older and meet one of three BMI-based criteria. Your prescriber sends the prescription, completes prior authorization if requested, and certifies that you are using the drug alongside a lifestyle program focused on diet and exercise.

It depends on your state. KFF reports that a federal model (called BALANCE) began implementation for state Medicaid programs in May 2026, with a negotiated price, while the matching Part D version was indefinitely delayed. Your state Medicaid office is the only reliable answer for your situation.